Eli Lilly's most recent trend suggests a bearish bias. One trading opportunity on Eli Lilly is a Bear Call Spread using a strike $108.00 short call and a strike $113.00 long call offers a potential 35.14% return on risk over the next 10 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $108.00 by expiration. The full premium credit of $1.30 would be kept by the premium seller. The risk of $3.70 would be incurred if the stock rose above the $113.00 long call strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.
The RSI indicator is at 38.8 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Economic Calendar – Top 5 Things to Watch This Week
Sun, 04 Nov 2018 12:39:00 +0000
Investing.com – Politics and trade rhetoric could hang over the market in the coming week, as investors look ahead to U.S. midterm elections, in which polls suggest the Democratic Party will win control of the House of Representatives.
AMAG Posts Wider-Than-Expected Q3 Loss, Beats on Revenues
Fri, 02 Nov 2018 22:11:10 +0000
AMAG reports wider than expected loss in the third quarter of 2018. The company completed the sale of Cord Blood Registry in August 2018.
A Look at Merck’s Diabetes and Women’s Health Business
Fri, 02 Nov 2018 14:30:18 +0000
Merck & Co.’s (MRK) Januvia generated revenues of $927 million in the third quarter, reflecting an ~8% YoY (year-over-year) decline. In the US and international markets, Januvia generated revenues of $498 million and $429 million, respectively, reflecting a ~17% YoY decline and a ~45 YoY growth.
Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus
Fri, 02 Nov 2018 12:09:12 +0000
Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.
Zoetis (ZTS) Beats on Q3 Earnings & Sales, Updates '18 View
Thu, 01 Nov 2018 20:50:08 +0000
Zoetis (ZTS) beats both earnings and sales estimates in the third quarter of 2018. The company also updates its 2018 outlook.
Also on Market Tamer…
Follow Us on Facebook